Allan E. Rettie - Publications

University of Washington, Seattle, Seattle, WA 
Pharmacology, Biochemistry

145 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Cox EJ, Tian DD, Clarke JD, Rettie AE, Unadkat JD, Thummel KE, McCune JS, Paine MF. Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach. Pharmacological Reviews. 73: 847-859. PMID 33712517 DOI: 10.1124/pharmrev.120.000106  0.4
2021 Henderson LM, Hopkins SE, Boyer BB, Thornton TA, Rettie AE, Thummel KE. Functional Effects of , a Novel and Common Variant in the Yup'ik Alaska Native Population. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 33632714 DOI: 10.1124/dmd.120.000301  0.4
2020 Tanna RS, Tian DD, Cech NB, Oberlies NH, Rettie AE, Thummel KE, Paine MF. Refined prediction of pharmacokinetic kratom-drug interactions: time-dependent inhibition considerations. The Journal of Pharmacology and Experimental Therapeutics. PMID 33093187 DOI: 10.1124/jpet.120.000270  0.4
2020 Imaoka T, Yang J, Wang L, McDonald MG, Afsharinejad Z, Bammler TK, Van Ness K, Yeung CK, Rettie AE, Himmelfarb J, Kelly EJ. Microphysiological System Modeling of Ochratoxin A-Associated Nephrotoxicity. Toxicology. 152582. PMID 32905824 DOI: 10.1016/j.tox.2020.152582  0.96
2020 McDonald MG, Tian DD, Thummel KE, Paine MF, Rettie AE. Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 32591416 DOI: 10.1124/dmd.120.091041  0.4
2020 McDonald MG, Henderson LM, Ray S, Yeung CK, Johnson AL, Kowalski JP, Hanenberg H, Wiek C, Thummel KE, Rettie AE. Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People. The Journal of Pharmacology and Experimental Therapeutics. PMID 32423989 DOI: 10.1124/jpet.120.265850  0.96
2020 Kowalski JP, McDonald MG, Pelletier RD, Hanenberg H, Wiek C, Rettie AE. Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1. Journal of Medicinal Chemistry. PMID 32302132 DOI: 10.1021/acs.jmedchem.0c00101  0.4
2019 Kowalski JP, McDonald MG, Whittington D, Guttman M, Scian M, Girhard M, Hanenberg H, Wiek C, Rettie AE. Structure-Activity Relationships for CYP4B1 Bioactivation of 4-Ipomeanol Congeners: Direct Correlation between Cytotoxicity and Trapped Reactive Intermediates. Chemical Research in Toxicology. PMID 31799839 DOI: 10.1021/acs.chemrestox.9b00330  0.4
2019 Dalton R, Lee SB, Claw KG, Prasad B, Phillips BR, Shen DD, Hong Wong L, Fade M, McDonald MG, Dunham MJ, Fowler DM, Rettie AE, Schuetz E, Thornton TA, Nickerson DA, et al. Interrogation of CYP2D6 structural variant alleles improves the correlation between CYP2D6 genotype and CYP2D6-mediated metabolic activity. Clinical and Translational Science. PMID 31536170 DOI: 10.1111/cts.12695  0.4
2019 Henderson LM, Robinson RF, Ray L, Li T, Dillard DA, Schilling BD, Mosley M, Janssen PL, Fohner AE, Rettie AE, Thummel KE, Thornton TA, Veenstra DL. VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. Clinical and Translational Science. PMID 30821933 DOI: 10.1111/cts.12611  0.4
2019 McDonald MG, Yeung CK, Teitelbaum AM, Johnson AL, Fujii S, Kagechika H, Rettie AE. A New LC-MS Assay for the Quantitative Analysis of Vitamin K Metabolites in Human Urine. Journal of Lipid Research. PMID 30670472 DOI: 10.1194/jlr.D087916  0.96
2018 Teitelbaum AM, McDonald MG, Kowalski JP, Parkinson OT, Scian M, Whittington D, Roellecke K, Hanenberg H, Wiek C, Rettie AE. Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol. The Journal of Pharmacology and Experimental Therapeutics. PMID 30409834 DOI: 10.1124/jpet.118.249771  0.4
2017 Au NT, Ryman T, Rettie AE, Hopkins SE, Boyer BB, Black J, Philip J, Yracheta J, Fohner AE, Reyes M, Thornton TA, Austin MA, Thummel KE. Dietary Vitamin K and Association with Hepatic Vitamin K Status in a Yup'ik Study Population from Southwestern Alaska. Molecular Nutrition & Food Research. PMID 29094808 DOI: 10.1002/mnfr.201700746  0.4
2017 McDonald MG, Ray S, Amorosi CJ, Sitko KA, Kowalski JP, Paco L, Nath A, Gallis BM, Totah RA, Dunham MJ, Fowler DM, Rettie AE. Expression and functional characterization of breast cancer-associated cytochrome P450 4Z1 in Saccharomyces cerevisiae. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 29018033 DOI: 10.1124/dmd.117.078188  0.4
2017 Xu M, Bhatt DK, Yeung CK, Claw KG, Chaudhry AS, Gaedigk A, Pearce RE, Broeckel U, Gaedigk R, Nickerson D, Schuetz E, Rettie AE, Leeder S, Thummel KE, Prasad B. Genetic and Non-genetic Factors Associated with Protein Abundance of Flavin-containing Monooxygenase 3 in Human Liver. The Journal of Pharmacology and Experimental Therapeutics. PMID 28819071 DOI: 10.1124/jpet.117.243113  0.96
2017 Lockhart CM, Smith TB, Yang P, Naidu M, Rettie AE, Nath A, Weleber R, Kelly EJ. Longitudinal characterisation of function and structure of Bietti crystalline dystrophy: report on a novel homozygous mutation in CYP4V2. The British Journal of Ophthalmology. PMID 28698241 DOI: 10.1136/bjophthalmol-2016-309696  0.64
2017 Au NT, Reyes M, Boyer BB, Hopkins SE, Black J, O'Brien D, Fohner AE, Yracheta J, Thornton T, Austin MA, Burke W, Thummel KE, Rettie AE. Dietary and genetic influences on hemostasis in a Yup'ik Alaska Native population. Plos One. 12: e0173616. PMID 28376131 DOI: 10.1371/journal.pone.0173616  0.4
2017 Hsu MH, Baer BR, Rettie AE, Johnson EF. The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monoxygenase Complexed with Octane Discloses Several Structural Adaptations for ω-Hydroxylation. The Journal of Biological Chemistry. PMID 28167536 DOI: 10.1074/jbc.M117.775494  0.36
2016 Flora DR, Rettie AE, Brundage RC, Tracy TS. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites. Journal of Clinical Pharmacology. PMID 27539372 DOI: 10.1002/jcph.813  0.48
2016 Robinson-Cohen C, Newitt R, Shen DD, Rettie AE, Kestenbaum BR, Himmelfarb J, Yeung CK. Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients. Plos One. 11: e0161074. PMID 27513517 DOI: 10.1371/journal.pone.0161074  0.96
2016 Parkinson OT, Teitelbaum AM, Whittington D, Kelly EJ, Rettie AE. Species Differences in Microsomal Oxidation and Glucuronidation of 4-Ipomeanol: Relationship to Target Organ Toxicity. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27468999 DOI: 10.1124/dmd.116.070003  0.64
2015 Teitelbaum AM, Scian M, Nelson WL, Rettie AE. Efficient Syntheses of Vitamin K Chain-Shortened Acid Metabolites. Synthesis. 47: 944-948. PMID 27003951 DOI: 10.1055/s-0034-1380002  1
2015 Schmidt EM, Wiek C, Parkinson OT, Roellecke K, Freund M, Gombert M, Lottmann N, Steward CA, Kramm CM, Yarov-Yarovoy V, Rettie AE, Hanenberg H. Characterization of an Additional Splice Acceptor Site Introduced into CYP4B1 in Hominoidae during Evolution. Plos One. 10: e0137110. PMID 26355749 DOI: 10.1371/journal.pone.0137110  1
2015 McDonald MG, Au NT, Rettie AE. P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 1661-9. PMID 26296708 DOI: 10.1124/dmd.115.065623  1
2015 Parra EJ, Botton MR, Perini JA, Krithika S, Bourgeois S, Johnson TA, Tsunoda T, Pirmohamed M, Wadelius M, Limdi NA, Cavallari LH, Burmester JK, Rettie AE, Klein TE, Johnson JA, et al. Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics. 16: 1-11. PMID 26265036 DOI: 10.2217/PGS.15.73  1
2015 Johnson AL, Edson KZ, Totah RA, Rettie AE. Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer. Advances in Pharmacology (San Diego, Calif.). 74: 223-62. PMID 26233909 DOI: 10.1016/bs.apha.2015.05.002  0.36
2015 Fohner AE, Robinson R, Yracheta J, Dillard DA, Schilling B, Khan B, Hopkins S, Boyer BB, Black J, Wiener H, Tiwari HK, Gordon A, Nickerson D, Tsai JM, Farin FM, ... ... Rettie AE, et al. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenetics and Genomics. 25: 343-53. PMID 25946405 DOI: 10.1097/FPC.0000000000000143  1
2015 Wiek C, Schmidt EM, Roellecke K, Freund M, Nakano M, Kelly EJ, Kaisers W, Yarov-Yarovoy V, Kramm CM, Rettie AE, Hanenberg H. Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol. The Biochemical Journal. 465: 103-14. PMID 25247810 DOI: 10.1042/BJ20140813  1
2015 Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content Pharmacogenomics Journal. DOI: 10.1038/tpj.2015.58  1
2015 Johnson AL, Edson KZ, Totah RA, Rettie AE. Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer Advances in Pharmacology. DOI: 10.1016/bs.apha.2015.05.002  1
2014 Marsillach J, Suzuki SM, Richter RJ, McDonald MG, Rademacher PM, MacCoss MJ, Hsieh EJ, Rettie AE, Furlong CE. Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase. Plos One. 9: e110054. PMID 25333274 DOI: 10.1371/journal.pone.0110054  1
2014 Lockhart CM, Nakano M, Rettie AE, Kelly EJ. Generation and characterization of a murine model of Bietti crystalline dystrophy. Investigative Ophthalmology & Visual Science. 55: 5572-81. PMID 25118264 DOI: 10.1167/iovs.13-13717  1
2014 Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clinical Pharmacology and Therapeutics. 96: 542-8. PMID 25099164 DOI: 10.1038/clpt.2014.159  1
2014 Nakano M, Lockhart CM, Kelly EJ, Rettie AE. Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition. Drug Metabolism Reviews. 46: 247-60. PMID 24856391 DOI: 10.3109/03602532.2014.921190  1
2014 Roth JA, Boudreau D, Fujii MM, Farin FM, Rettie AE, Thummel KE, Veenstra DL. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clinical Pharmacology and Therapeutics. 95: 636-43. PMID 24503627 DOI: 10.1038/clpt.2014.26  1
2014 Haque JA, McDonald MG, Kulman JD, Rettie AE. A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites. Blood. 123: 582-9. PMID 24297869 DOI: 10.1182/blood-2013-05-505123  1
2014 Hardy KD, Wahlin MD, Papageorgiou I, Unadkat JD, Rettie AE, Nelson SD. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 162-71. PMID 24191259 DOI: 10.1124/dmd.113.054817  1
2013 Pandey RN, Wang TS, Tadjuidje E, McDonald MG, Rettie AE, Hegde RS. Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents. Plos One. 8: e84582. PMID 24367676 DOI: 10.1371/journal.pone.0084582  1
2013 Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie AE, Khojasteh C, McGlothlin D, Wu AH, Hsueh WC, Witte JS, et al. Association of CYP2C9*2 with bosentan-induced liver injury. Clinical Pharmacology and Therapeutics. 94: 678-86. PMID 23863877 DOI: 10.1038/clpt.2013.143  1
2013 Parkinson OT, Liggitt HD, Rettie AE, Kelly EJ. Generation and characterization of a Cyp4b1 null mouse and the role of CYP4B1 in the activation and toxicity of Ipomeanol. Toxicological Sciences : An Official Journal of the Society of Toxicology. 134: 243-50. PMID 23748241 DOI: 10.1093/toxsci/kft123  1
2013 Farley SM, Leonard SW, Taylor AW, Birringer M, Edson KZ, Rettie AE, Traber MG. ω-Hydroxylation of phylloquinone by CYP4F2 is not increased by α-tocopherol. Molecular Nutrition & Food Research. 57: 1785-93. PMID 23650179 DOI: 10.1002/mnfr.201200797  1
2013 Baker PE, Cole TB, Cartwright M, Suzuki SM, Thummel KE, Lin YS, Co AL, Rettie AE, Kim JH, Furlong CE. Identifying safer anti-wear triaryl phosphate additives for jet engine lubricants. Chemico-Biological Interactions. 203: 257-64. PMID 23085349 DOI: 10.1016/j.cbi.2012.10.005  1
2012 Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, et al. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clinical Pharmacology and Therapeutics. 92: 746-56. PMID 23132553 DOI: 10.1038/clpt.2012.184  1
2012 Nakano M, Kelly EJ, Wiek C, Hanenberg H, Rettie AE. CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant. Molecular Pharmacology. 82: 679-86. PMID 22772592 DOI: 10.1124/mol.112.080085  1
2012 McDonald MG, Au NT, Wittkowsky AK, Rettie AE. Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites. Clinical Pharmacology and Therapeutics. 91: 709-17. PMID 22398967 DOI: 10.1038/clpt.2011.283  1
2012 Parkinson OT, Kelly EJ, Bezabih E, Whittington D, Rettie AE. Bioactivation of 4-Ipomeanol by a CYP4B enzyme in bovine lung and inhibition by HET0016. Journal of Veterinary Pharmacology and Therapeutics. 35: 402-5. PMID 21919916 DOI: 10.1111/j.1365-2885.2011.01339.x  1
2011 Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, Mirkov S, Ramirez J, Liu W, Lin YS, Moloney C, Aldred SF, Trinklein ND, Schuetz E, Nickerson DA, Thummel KE, ... ... Rettie AE, et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. Plos Genetics. 7: e1002078. PMID 21637794 DOI: 10.1371/journal.pgen.1002078  1
2011 Kelly EJ, Nakano M, Rohatgi P, Yarov-Yarovoy V, Rettie AE. Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states. Molecular Interventions. 11: 124-32. PMID 21540472 DOI: 10.1124/mi.11.2.10  1
2011 Baillie TA, Rettie AE. Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metabolism and Pharmacokinetics. 26: 15-29. PMID 20978360 DOI: JST.JSTAGE/dmpk/DMPK-10-RV-089  1
2010 Roberts AG, Cheesman MJ, Primak A, Bowman MK, Atkins WM, Rettie AE. Intramolecular heme ligation of the cytochrome P450 2C9 R108H mutant demonstrates pronounced conformational flexibility of the B-C loop region: implications for substrate binding. Biochemistry. 49: 8700-8. PMID 20815369 DOI: 10.1021/bi100911q  1
2009 Choppin A, Irwin I, Lach L, McDonald MG, Rettie AE, Shao L, Becker C, Palme MP, Paliard X, Bowersox S, Dennis DM, Druzgala P. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. British Journal of Pharmacology. 158: 1536-47. PMID 19845677 DOI: 10.1111/j.1476-5381.2009.00420.x  1
2009 Nakano M, Kelly EJ, Rettie AE. Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 2119-22. PMID 19661213 DOI: 10.1124/dmd.109.028530  1
2009 McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Molecular Pharmacology. 75: 1337-46. PMID 19297519 DOI: 10.1124/mol.109.054833  1
2009 Mosher CM, Tai G, Rettie AE. CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry. The Journal of Pharmacology and Experimental Therapeutics. 329: 938-44. PMID 19258521 DOI: 10.1124/jpet.109.150706  1
2008 Mosher CM, Hummel MA, Tracy TS, Rettie AE. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9. Biochemistry. 47: 11725-34. PMID 18922023 DOI: 10.1021/bi801231m  1
2008 Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients Thrombosis and Haemostasis. 100: 229-239. PMID 18690342 DOI: 10.1160/TH07-09-0552  1
2008 Tai G, Dickmann LJ, Matovic N, DeVoss JJ, Gillam EM, Rettie AE. Re-engineering of CYP2C9 to probe acid-base substrate selectivity. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1992-7. PMID 18606741 DOI: 10.1124/dmd.108.022186  1
2008 Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 112: 1022-7. PMID 18535201 DOI: 10.1182/blood-2008-01-134247  1
2008 Kramer MA, Rettie AE, Rieder MJ, Cabacungan ET, Hines RN. Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Molecular Pharmacology. 73: 1751-60. PMID 18310303 DOI: 10.1124/mol.107.044149  1
2008 Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical Pharmacology and Therapeutics. 84: 326-31. PMID 18305455 DOI: 10.1038/clpt.2008.10  1
2007 McDonald MG, Rettie AE. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chemical Research in Toxicology. 20: 1833-42. PMID 18020424 DOI: 10.1021/tx7001228  1
2007 Baer BR, Kunze KL, Rettie AE. Mechanism of formation of the ester linkage between heme and Glu310 of CYP4B1: 18O protein labeling studies. Biochemistry. 46: 11598-605. PMID 17880109 DOI: 10.1021/bi701064b  1
2007 Rieder MJ, Reiner AP, Rettie AE. γ-Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose Journal of Thrombosis and Haemostasis. 5: 2227-2234. PMID 17764537 DOI: 10.1111/j.1538-7836.2007.02744.x  1
2007 Yeung CK, Adman ET, Rettie AE. Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria. Archives of Biochemistry and Biophysics. 464: 251-9. PMID 17531949 DOI: 10.1016/  1
2006 Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. Molecular Interventions. 6: 223-7. PMID 16960144 DOI: 10.1124/mi.6.4.8  1
2006 Baer BR, Rettie AE. CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism. Drug Metabolism Reviews. 38: 451-76. PMID 16877261 DOI: 10.1080/03602530600688503  1
2006 Rettie AE, Farin FM, Beri NG, Srinouanprachanh SL, Rieder MJ, Thijssen HH. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9 British Journal of Clinical Pharmacology. 62: 617-620. PMID 16869821 DOI: 10.1111/j.1365-2125.2006.02688.x  1
2006 Genter MB, Yost GS, Rettie AE. Localization of CYP4B1 in the rat nasal cavity and analysis of CYPs as secreted proteins. Journal of Biochemical and Molecular Toxicology. 20: 139-41. PMID 16788951 DOI: 10.1002/jbt.20123  1
2006 Yeung CK, Rettie AE. Prochiral sulfoxidation as a probe for flavin-containing monooxygenases. Methods in Molecular Biology (Clifton, N.J.). 320: 163-72. PMID 16719389 DOI: 10.1385/1-59259-998-2:163  1
2006 Yeung CK, Rettie AE. Benzydamine N-oxygenation as a measure of flavin-containing monooxygenase activity. Methods in Molecular Biology (Clifton, N.J.). 320: 157-62. PMID 16719388 DOI: 10.1385/1-59259-998-2:157  1
2006 Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 880-6. PMID 16467132 DOI: 10.1124/dmd.105.008672  1
2006 Yeung CK, Rettie AE, Thummel KE. Polymorphisms in Cytochrome P450 and Flavin-Containing Monooxygenase Genes Gene-Environment Interactions: Fundamentals of Ecogenetics. 95-126. DOI: 10.1002/0471758043.ch7  1
2006 Totah RA, Rettie AE. Principles of drug metabolism 3: Enzymes and tissues Comprehensive Medicinal Chemistry Ii. 5: 167-191.  1
2005 Baer BR, Schuman JT, Campbell AP, Cheesman MJ, Nakano M, Moguilevsky N, Kunze KL, Rettie AE. Sites of covalent attachment of CYP4 enzymes to heme: evidence for microheterogeneity of P450 heme orientation. Biochemistry. 44: 13914-20. PMID 16229480 DOI: 10.1021/bi051267j  1
2005 Veenstra DL, You JHS, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogenetics and Genomics. 15: 687-691. PMID 16141794  1
2005 Tai G, Farin F, Rieder MJ, Dreisbach AW, Veenstra DL, Verlinde CL, Rettie AE. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenetics and Genomics. 15: 475-81. PMID 15970795  0.96
2005 Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher CM, Rettie AE, Tracy TS. CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Molecular Pharmacology. 68: 644-51. PMID 15955872 DOI: 10.1124/mol.105.013763  1
2005 Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England Journal of Medicine. 352: 2285-93. PMID 15930419 DOI: 10.1056/NEJMoa044503  1
2005 Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ, Rettie AE. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clinical Pharmacology and Therapeutics. 77: 353-64. PMID 15900281 DOI: 10.1016/j.clpt.2005.01.019  1
2005 Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clinical Pharmacology and Therapeutics. 77: 341-52. PMID 15900280 DOI: 10.1016/j.clpt.2004.12.267  1
2005 Baer BR, Rettie AE, Henne KR. Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate. Chemical Research in Toxicology. 18: 855-64. PMID 15892579 DOI: 10.1021/tx0496993  1
2005 Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annual Review of Pharmacology and Toxicology. 45: 477-94. PMID 15822186 DOI: 10.1146/annurev.pharmtox.45.120403.095821  1
2004 Locuson CW, Suzuki H, Rettie AE, Jones JP. Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. Journal of Medicinal Chemistry. 47: 6768-76. PMID 15615526 DOI: 10.1021/jm049605m  1
2004 Suzuki H, Kneller MB, Rock DA, Jones JP, Trager WF, Rettie AE. Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Archives of Biochemistry and Biophysics. 429: 1-15. PMID 15288804 DOI: 10.1016/  1
2004 Schlenk D, Yeung C, Rettie A. Unique monooxygenation pattern indicates novel flavin-containing monooxygenase in liver of rainbow trout. Marine Environmental Research. 58: 499-503. PMID 15178073 DOI: 10.1016/j.marenvres.2004.03.036  1
2004 Hummel MA, Dickmann LJ, Rettie AE, Haining RL, Tracy TS. Differential activation of CYP2C9 variants by dapsone. Biochemical Pharmacology. 67: 1831-41. PMID 15130760 DOI: 10.1016/j.bcp.2004.01.017  1
2004 Dickmann LJ, Locuson CW, Jones JP, Rettie AE. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Molecular Pharmacology. 65: 842-50. PMID 15044613 DOI: 10.1124/mol.65.4.842  1
2003 Cheesman MJ, Byron Kneller M, Rettie AE. Critical role of histidine residues in cyclohexanone monooxygenase expression, cofactor binding and catalysis. Chemico-Biological Interactions. 146: 157-64. PMID 14597129  0.36
2003 Cheesman MJ, Baer BR, Zheng YM, Gillam EM, Rettie AE. Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group. Archives of Biochemistry and Biophysics. 416: 17-24. PMID 12859977 DOI: 10.1016/S0003-9861(03)00278-9  1
2003 Zheng YM, Baer BR, Kneller MB, Henne KR, Kunze KL, Rettie AE. Covalent heme binding to CYP4B1 via Glu310 and a carbocation porphyrin intermediate. Biochemistry. 42: 4601-6. PMID 12693958 DOI: 10.1021/bi020667t  1
2003 Rettie AE, Tai G, Veenstra DL, Farin FM, Srinouanprachan S, Lin YS, Thummel KE, Hines RN. CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians. Blood. 101: 2896-7. PMID 12642346 DOI: 10.1182/blood-2002-11-3452  1
2003 Zheng YM, Henne KR, Charmley P, Kim RB, McCarver DG, Cabacungan ET, Hines RN, Rettie AE. Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicology and Applied Pharmacology. 186: 119-26. PMID 12639503 DOI: 10.1016/S0041-008X(02)00028-5  1
2002 Yu A, Kneller BM, Rettie AE, Haining RL. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. The Journal of Pharmacology and Experimental Therapeutics. 303: 1291-300. PMID 12438554 DOI: 10.1124/jpet.102.039891  1
2002 Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama. 287: 1690-8. PMID 11926893  1
2002 Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 385-90. PMID 11901091 DOI: 10.1124/dmd.30.4.385  1
2002 Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 235-9. PMID 11854139  1
2002 Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatric Research. 51: 236-43. PMID 11809920 DOI: 10.1203/00006450-200202000-00018  0.96
2002 Schlenk D, Cashman JR, Yeung C, Zhang X, Rettie AE. Role of human flavin-containing monooxygenases in the sulfoxidation of [14C]aldicarb Pesticide Biochemistry and Physiology. 73: 67-73. DOI: 10.1016/S0048-3575(02)00013-5  1
2001 Henne KR, Kunze KL, Zheng YM, Christmas P, Soberman RJ, Rettie AE. Covalent linkage of prosthetic heme to CYP4 family P450 enzymes. Biochemistry. 40: 12925-31. PMID 11669629 DOI: 10.1021/bi011171z  1
2001 Gartner CA, Thompson SJ, Rettie AE, Nelson SD. Human aromatase in high yield and purity by perfusion chromatography and its characterization by difference spectroscopy and mass spectrometry. Protein Expression and Purification. 22: 443-54. PMID 11483007 DOI: 10.1006/prep.2001.1464  1
2001 Christmas P, Jones JP, Patten CJ, Rock DA, Zheng Y, Cheng SM, Weber BM, Carlesso N, Scadden DT, Rettie AE, Soberman RJ. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. The Journal of Biological Chemistry. 276: 38166-72. PMID 11461919 DOI: 10.1074/jbc.M104818200  1
2001 Henne KR, Fisher MB, Iyer KR, Lang DH, Trager WF, Rettie AE. Active site characteristics of CYP4B1 probed with aromatic ligands. Biochemistry. 40: 8597-605. PMID 11456500 DOI: 10.1021/bi010395e  1
2001 Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Molecular Pharmacology. 60: 382-7. PMID 11455026  1
2001 Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. Journal of Clinical Pharmacology. 41: 715-22. PMID 11452703 DOI: 10.1177/00912700122010618  1
2001 He M, Rettie AE, Neal J, Trager WF. Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 29: 701-11. PMID 11302937  1
2001 Cheesman MJ, Kneller MB, Kelly EJ, Thompson SJ, Yeung CK, Eaton DL, Rettie AE. Purification and characterization of hexahistidine-tagged cyclohexanone monooxygenase expressed in Saccharomyces cerevisiae and Escherichia coli. Protein Expression and Purification. 21: 81-6. PMID 11162390 DOI: 10.1006/prep.2000.1340  1
2000 Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, Jones JP. A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. Journal of Medicinal Chemistry. 43: 2789-96. PMID 10956186 DOI: 10.1021/jm000048n  1
2000 Yeung CK, Lang DH, Thummel KE, Rettie AE. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 28: 1107-11. PMID 10950857  1
2000 Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE, Hall SD. Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases: Comparison of human liver and kidney microsomes and mammalian enzymes Biochemical Pharmacology. 60: 7-17. PMID 10807940 DOI: 10.1016/S0006-2952(00)00301-4  1
1999 He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Archives of Biochemistry and Biophysics. 372: 16-28. PMID 10562412 DOI: 10.1006/abbi.1999.1468  1
1999 Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin Epilepsy Research. 35: 253-255. PMID 10413320 DOI: 10.1016/S0920-1211(99)00017-0  1
1999 Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, Rettie AE. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry. 38: 3285-92. PMID 10079071 DOI: 10.1021/bi982161+  1
1999 Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry. 38: 2312-9. PMID 10029524 DOI: 10.1021/bi9823030  1
1998 Lang DH, Yeung CK, Peter RM, Ibarra C, Gasser R, Itagaki K, Philpot RM, Rettie AE. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochemical Pharmacology. 56: 1005-12. PMID 9776311 DOI: 10.1016/S0006-2952(98)00218-4  1
1998 Zheng YM, Fisher MB, Yokotani N, Fujii-Kuriyama Y, Rettie AE. Identification of a meander region proline residue critical for heme binding to cytochrome P450: Implications for the catalytic function of human CYP4B1 Biochemistry. 37: 12847-12851. PMID 9737862 DOI: 10.1021/bi981280m  1
1998 Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. Journal of Chromatography. B, Biomedical Sciences and Applications. 710: 143-8. PMID 9686881 DOI: 10.1016/S0378-4347(98)00099-1  1
1998 Fisher MB, Thompson SJ, Ribeiro V, Lechner MC, Rettie AE. P450-catalyzed in-chain desaturation of valproic acid: Isoform selectivity and mechanism of formation of δ3-valproic acid generated by baculovirus-expressed CYP3A1 Archives of Biochemistry and Biophysics. 356: 63-70. PMID 9681992 DOI: 10.1006/abbi.1998.0742  1
1998 Fisher MB, Zheng YM, Rettie AE. Positional specificity of rabbit CYP4B1 for ω-hydroxylation of short-medium chain fatty acids and hydrocarbons Biochemical and Biophysical Research Communications. 248: 352-355. PMID 9675139 DOI: 10.1006/bbrc.1998.8842  1
1998 Guan X, Fisher MB, Lang DH, Zheng YM, Koop DR, Rettie AE. Cytochrome P450-dependent desaturation of lauric acid: isoform selectivity and mechanism of formation of 11-dodecenoic acid. Chemico-Biological Interactions. 110: 103-21. PMID 9566728 DOI: 10.1016/S0009-2797(97)00145-2  1
1998 Chen W, Koenigs LL, Thompson SJ, Peter RM, Rettie AE, Trager WF, Nelson SD. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6 Chemical Research in Toxicology. 11: 295-301. PMID 9548799 DOI: 10.1021/tx9701687  1
1998 Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, Tracy TS. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry. 37: 4137-47. PMID 9521735 DOI: 10.1021/bi9715627  1
1997 Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 25: 1407-15. PMID 9394031  1
1997 Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 7: 361-7. PMID 9352571 DOI: 10.1097/00008571-199710000-00004  1
1997 Fisher MB, Rettie AE. Prochiral sulfide probes for the active-site topography of rabbit flavin-containing monooxygenase 2 (FMO2) Tetrahedron Asymmetry. 8: 613-618. DOI: 10.1016/S0957-4166(97)00033-5  1
1996 Jones JP, He M, Trager WF, Rettie AE. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 24: 1-6. PMID 8825183  1
1996 Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Archives of Biochemistry and Biophysics. 333: 447-58. PMID 8809086 DOI: 10.1006/abbi.1996.0414  1
1996 Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 24: 610-4. PMID 8723744  1
1995 Slone DH, Gallagher EP, Ramsdell HS, Rettie AE, Stapleton PL, Berlad LG, Eaton DL. Human variability in hepatic glutathione S-transferase-mediated conjugation of aflatoxin B1-epoxide and other substrates. Pharmacogenetics. 5: 224-33. PMID 8528269 DOI: 10.1097/00008571-199508000-00006  1
1995 Rettie AE, Sheffels PR, Korzekwa KR, Gonzalez FJ, Philpot RM, Baillie TA. CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid. Biochemistry. 34: 7889-95. PMID 7794900 DOI: 10.1021/bi00024a013  1
1994 Rettie AE, Lawton MP, Sadeque AJ, Meier GP, Philpot RM. Prochiral sulfoxidation as a probe for multiple forms of the microsomal flavin-containing monooxygenase: studies with rabbit FMO1, FMO2, FMO3, and FMO5 expressed in Escherichia coli. Archives of Biochemistry and Biophysics. 311: 369-77. PMID 8203899 DOI: 10.1006/abbi.1994.1250  1
1994 Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 4: 39-42. PMID 8004131  1
1994 Yang HY, Lee QP, Rettie AE, Juchau MR. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Molecular Pharmacology. 46: 922-8. PMID 7969081  1
1994 Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, Vandenbranden M, Wrighton SA. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 22: 975-8. PMID 7895619  1
1993 Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, Cashman JR. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metabolism Reviews. 25: 453-84. PMID 8313838 DOI: 10.3109/03602539308993982  1
1992 Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Craig Eddy A, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin - Drug interactions Chemical Research in Toxicology. 5: 54-59. PMID 1581537  1
1990 Lawrence RF, Rettie AE, Eddy AC, Trager WF. Chemical synthesis, absolute configuration, and stereochemistry of formation of 10-hydroxywarfarin: a major oxidative metabolite of (+)-(R)-warfarin from hepatic microsomal preparations. Chirality. 2: 96-105. PMID 2400642 DOI: 10.1002/chir.530020207  1
1990 Jones JP, Rettie AE, Trager WF. Intrinsic isotope effects suggest that the reaction coordinate symmetry for the cytochrome P-450 catalyzed hydroxylation of octane is isozyme independent. Journal of Medicinal Chemistry. 33: 1242-6. PMID 2319565  1
1989 Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 17: 265-70. PMID 2568906  1
1989 Kerr BM, Rettie AE, Craig Eddy A, Loiseau P, Guyot M, Wilensky AJ, H. Levy R. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation Clinical Pharmacology and Therapeutics. 46: 82-93. PMID 2501059 DOI: 10.1038/clpt.1989.110  1
1987 Correia MA, Decker C, Sugiyama K, Caldera P, Bornheim L, Wrighton SA, Rettie AE, Trager WF. Degradation of rat hepatic cytochrome P-450 heme by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine to irreversibly bound protein adducts. Archives of Biochemistry and Biophysics. 258: 436-51. PMID 3674884  1
1987 O'Reilly RA, Trager WF, Rettie AE, Goulart DA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clinical Pharmacology and Therapeutics. 42: 290-4. PMID 3621782  1
1987 Bornheim LM, Underwood MC, Caldera P, Rettie AE, Trager WF, Wrighton SA, Correia MA. Inactivation of multiple hepatic cytochrome P-450 isozymes in rats by allylisopropylacetamide: mechanistic implications. Molecular Pharmacology. 32: 299-308. PMID 3302670  1
1986 Dean PA, Rettie AE, Turnblom SM, Namkung MJ, Juchau MR. Cytosolic activation of hematin-dependent microsomal monooxygenase activity in the lung. Chemico-Biological Interactions. 58: 79-94. PMID 3708723  1
1986 Rettie AE, Rettenmeier AW, Beyer BK, Baillie TA, Juchau MR. Valproate hydroxylation by human fetal tissues and embryotoxicity of metabolites. Clinical Pharmacology and Therapeutics. 40: 172-7. PMID 3089669  1
1985 Rettie AE, Heimark L, Mayer RT, Burke MD, Trager WF, Juchau MR. Stereoselective and regioselective hydroxylation of warfarin and selective O-dealkylation of phenoxazone ethers in human placenta. Biochemical and Biophysical Research Communications. 126: 1013-21. PMID 3977899  1
Show low-probability matches.